Jiang, ZhongLohse, Christine M.Chu, Peigou G.Wu, Chin-LeeWoda, Bruce A.Rock, Kenneth L.Kwon, Eugene D.2022-08-232022-08-232008-04-172009-10-29<p>Cancer. 2008 Jun 15;112(12):2676-82. <a href="http://dx.doi.org/10.1002/cncr.23484">Link to article on publisher's site</a></p>0008-543X (Print)10.1002/cncr.2348418412154https://hdl.handle.net/20.500.14038/39143BACKGROUND: Whether an oncofetal protein, IMP3, can serve as a prognostic biomarker to predict metastasis for patients with localized papillary and chromophobe subtypes of renal cell carcinomas (RCCs) was investigated. METHODS: The expression of IMP3 in 334 patients with primary papillary and chromophobe RCC from multiple medical centers was evaluated by immunohistochemistry. The 317 patients with localized papillary and chromophobe RCCs were further evaluated for outcome analyses. RESULTS: IMP3 was significantly increased in a subset of localized papillary and chromophobe RCCs that subsequently metastasized. Patients with localized IMP3-positive tumors (n=33; 10%) were over 10 times more likely to metastasize (risk ratio [RR], 11.38; 95% confidence interval [CI], 5.40-23.96; PCONCLUSIONS: IMP3 is an independent prognostic biomarker that can be used to identify a subgroup of patients with localized papillary and chromophobe RCC who are at high risk for developing distant metastasis.en-USAntigens, NeoplasmCarcinoma, PapillaryCarcinoma, Renal CellDisease-Free SurvivalHumansKidney NeoplasmsNeoplasm ProteinsRNA-Binding ProteinsTumor Markers, BiologicalLife SciencesMedicine and Health SciencesJournal Articlehttps://escholarship.umassmed.edu/oapubs/19571050693oapubs/1957